Brind.

ImmunityBio's offering requires filing with the SEC, with the associated book-running office located in Minneapolis.

2 reports, 2 independent Updated Jun 29

Gone quiet

Reports: 2
Developments: 1
Repetition: 50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

ImmunityBio's offering requires filing with the SEC, with the associated book-running office located in Minneapolis.

Who's involved

What this event is mainly about

ImmunityBio SEC

Keep exploring

The entities involved

ImmunityBio
biotech company

Nothing else this week.
SEC
Slovak company
- DHS, DOJ, and SEC formed a joint initiative to establish a Trade Fraud Task Force, setting standards for compliance.Mon 17:57
- The Fidelis Partnership is incorporating in Bermuda and filing for an initial public offering on the NYSE, with principal offices in London and a main office in Dublin.Mon 17:12

Coverage

Newest first; wire copies grouped

Jun 29themarketsdaily.com
Jul 25Business WireImmunityBio, Inc. Announces Execution of $80 Million Equity Financing from Multiple Institutional Investors CULVER CITY, Calif., July 25, 2025--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a le